Previous Close | 1.7000 |
Open | 1.6500 |
Bid | 1.6300 |
Ask | 1.8100 |
Strike | 60.00 |
Expire Date | 2023-01-20 |
Day's Range | 1.4400 - 1.6500 |
Contract Range | N/A |
Volume | |
Open Interest | 41.94k |
Pfizer (PFE) submits NDA to the FDA seeking approval for using its oral antiviral COVID pill in vaccinated and unvaccinated patients at a high risk of developing severe COVID-19 complications.
In anticipation of a new surge of COVID-19 infections later this year, the FDA recommends that COVID-19 vaccine manufacturers develop bivalent booster vaccines that contain the BA.4/BA.5 Omicron subvariants.
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.